Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5371-5378

  Papo, Niv ^a   Seger, Dalia ^a   Makovitzki, Arik ^a   Kalchenko, Vyacheslav ^a   Eshhar, Zelig ^a   Degani, Hadassa ^a   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO AMINO ACID; DOXORUBICIN; PHOSPHATIDYLSERINE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CAPILLARY; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN CELL; IMAGING SYSTEM; INOCULATION; LUNG METASTASIS; MALE; METASTASIS; MICROVASCULATURE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BINDING; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; LEUCINE; LUNG NEOPLASMS; LYSINE; MALE; MEMBRANE POTENTIALS; MICE; MICE, SCID; NEOPLASM METASTASIS; PEPTIDES; PHOSPHATIDYLSERINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744916273     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4569     Document Type: Article

References (43)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 2004;299:267-78.
3. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
4. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995;13:61-92.
5. Hancock RE. Peptide antibiotics. Lancet 1997;349:418-22.
6. Ganz T, Lehrer RI. Antimicrobial peptides of vertebrates. Curr Opin Immunol 1998;10:41-4.
7. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95.
8. Ohsaki Y, Gazdar AF, Chen HC, Johnson BE. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 1992;52:3534-8.
9. Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001;61:2434-8.
10. Street SE, Cretney E, Smyth MJ. Perform and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
11. Ellerby HM, Lee S, Ellerby LM, et al. An artificially designed pore-forming protein with anti-tumor effects. J Biol Chem 2003;278:35311-6.
12. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003;78:17-27.
13. Papo N, Braunstein A, Eshhar Z, Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 2004;64:5779-86.
14. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994;6:584-9.
15. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999;15:1-2.
16. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999;1462:55-70.
17. Tossi A, Sandri L, Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers 2000;55:4-30.
18. Bulet P, Stocklin R, Menin L. Anti-microbial peptides: from invertebrates to vertebrates. Immunol Rev 2004;198:169-84.
19. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002;66:236-48.
20. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of D, L amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003;278:21018-23.
21. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-32.
22. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-88.
23. Chen HM, Wang W, Smith D, Chan SC. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochim Biophys Acta 1997;1336:171-9.
24. Chan SC, Yau WL, Wang W, Smith DK, Sheu FS, Chen HM. Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. J Pept Sci 1998;4:413-25.
25. Papo N, Shai Y. New lytic peptides based on the D, L amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003;42:9346-54.
26. Manno S, Takakuwa Y, Mohandas N. Identification of a functional role for lipid asymmetry in biological membranes: phosphatidylserine-skeletal protein interactions modulate membrane stability. Proc Natl Acad Sci U S A 2002;99:1943-8.
27. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
28. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res 1993;53:3052-7.
29. Patel BJ, Pantuck AJ, Zisman A, et al. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-5.
30. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9.
31. Okamoto M, Webber MM, Quader S, Oyasu R. Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate 1998;35:255-62.
32. Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51:73-83.
33. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
34. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 1993;150:1458-70.
35. Dadiani M, Margalit R, Sela N, Degani H. High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. Cancer Res 2004;64:3155-61.
36. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides: peptide properties and plausible modes of action. J Biol Chem 2006;281:1636-43.
37. Matz MV, Fradkov AF, Labas YA, et al. Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol 1999;17:969-73.
38. Pouny Y, Shai Y. Interaction of D-amino acid incorporated analogues of pardaxin with membranes. Biochemistry 1992;31:9482-90.
39. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003;63:382-5.
40. Van Blitterswijk WJ, De Veer G, Krol JH, Emmelot P. Comparative lipid analysis of purified plasma membranes and shed extracellular membrane vesicles from normal murine thymocytes and leukemic GRSL cells. Biochim Biophys Acta 1982;688:495-504.
41. Papo N, Oren Z, Pag U, Sahl HG, Shai Y. The consequence of sequence alteration of an amphipathic α-helical antimicrobial peptide and its diastereomers. J Biol Chem 2002;277:33913-21.
42. Papo N, Shai Y. Effect of drastic sequence alteration and D-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry 2004;43:6393-403.
43. Liu CC, Walsh CM, Young JD. Perform: structure and function. Immunol Today 1995;16:194-201.